Quantoom Biosciences develops a proprietary RNA manufacturing technology, Ntensify, which enables scalable mRNA production for drug substances and formulated products. Their solutions address the need for efficient and compliant mRNA bioproduction in drug discovery, pre-clinical research, and clinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
Current mRNA manufacturing processes often lack the scalability and efficiency required for rapid deployment in drug discovery, preclinical research, clinical trials, and commercial manufacturing. Traditional methods can be cumbersome, costly, and may not meet the stringent regulatory standards for therapeutic applications.
Solution
Quantoom Biosciences offers an integrated mRNA manufacturing platform, featuring its proprietary Ntensify technology, designed to streamline and scale mRNA production for various applications. Their solutions provide a turnkey approach to mRNA bioproduction, addressing the needs of drug discovery, preclinical research, clinical trials, and commercial manufacturing. Ncapsulate, an automated system for GMP mRNA formulation, ensures rigorous clinical and commercial standards are met.
Target Audience
Quantoom Biosciences primarily serves pharmaceutical companies, biotech firms, and research institutions involved in drug discovery, preclinical studies, clinical trials, and commercialization of mRNA-based therapeutics and vaccines.
Features
- Ntensify RNA manufacturing technology for seamless integration across various scales, from preclinical to large-scale manufacturing
- Ncapsulate automated system for GMP mRNA formulation, meeting rigorous clinical and commercial standards
- All-in-one mRNA production kits for research purposes
- mRNA production systems for drug discovery and pre-clinical research
- mRNA production systems for clinical trials and commercial manufacturing